Literature DB >> 20580132

A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease.

Suk Ling Ma1, Nelson Leung Sang Tang, Cindy Woon Chi Tam, Victor Wing Cheong Lui, Linda Chiu Wa Lam, Helen Fung Kum Chiu, Jane Ann Driver, Lucia Pastorino, Kun Ping Lu.   

Abstract

Alzheimer's disease (AD), the most common form of dementia, is characterized by the presence of neurofibrillary tangles composed of tau and senile plaques of amyloid-beta peptides (Aβ) derived from amyloid precursor protein (APP). Pin1 is a unique prolyl isomerase that has been shown to protect against age-dependent neurodegeneration by acting on phosphorylated tau and APP to suppress tangle formation and amyloidogenic APP processing. Here we report a functional polymorphism, rs2287839, in the Pin1 promoter that is significantly associated with a 3-year delay in the average age at onset (AAO) of late-onset AD in a Chinese population. More significantly, the Pin1 polymorphism rs2287839 is located within the consensus binding motif for the brain-selective transcription factor, AP4 (CAGCTG) and almost completely abolishes the ability of AP4 to bind and suppress the Pin1 promoter, as shown by chromatin immunoprecipitation, electrophoretic mobility shift assay, and promoter luciferase assay. Moreover, overexpression or knockdown of AP4 resulted in an 80% reduction or 2-fold increase in endogenous Pin1 levels, respectively. Thus, AP4 is a novel transcriptional repressor of Pin1 expression and the Pin1 promoter single nucleotide polymorphism (SNP) identified in this study that prevents such suppression is associated with delayed onset of AD. These results indicate that regulation of Pin1 by AP4 plays a critical role in determining age at onset of AD and might be a novel therapeutic target to delay the onset of AD. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580132      PMCID: PMC2988914          DOI: 10.1016/j.neurobiolaging.2010.05.018

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  62 in total

1.  Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity.

Authors:  Y F Hu; B Lüscher; A Admon; N Mermod; R Tjian
Journal:  Genes Dev       Date:  1990-10       Impact factor: 11.361

2.  Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent.

Authors:  R Ranganathan; K P Lu; T Hunter; J P Noel
Journal:  Cell       Date:  1997-06-13       Impact factor: 41.582

3.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

Authors:  R Brookmeyer; S Gray; C Kawas
Journal:  Am J Public Health       Date:  1998-09       Impact factor: 9.308

4.  Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL.

Authors:  T Heinemeyer; E Wingender; I Reuter; H Hermjakob; A E Kel; O V Kel; E V Ignatieva; E A Ananko; O A Podkolodnaya; F A Kolpakov; N L Podkolodny; N A Kolchanov
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

5.  Exon-I is involved in positive as well as negative regulation of human angiotensinogen gene expression.

Authors:  Y Cui; C S Narayanan; J Zhou; A Kumar
Journal:  Gene       Date:  1998-12-11       Impact factor: 3.688

6.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.

Authors:  P J Lu; G Wulf; X Z Zhou; P Davies; K P Lu
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

7.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

Authors:  D A Evans; H H Funkenstein; M S Albert; P A Scherr; N R Cook; M J Chown; L E Hebert; C H Hennekens; J O Taylor
Journal:  JAMA       Date:  1989-11-10       Impact factor: 56.272

8.  Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism.

Authors:  M B Yaffe; M Schutkowski; M Shen; X Z Zhou; P T Stukenberg; J U Rahfeld; J Xu; J Kuang; M W Kirschner; G Fischer; L C Cantley; K P Lu
Journal:  Science       Date:  1997-12-12       Impact factor: 47.728

9.  A human peptidyl-prolyl isomerase essential for regulation of mitosis.

Authors:  K P Lu; S D Hanes; T Hunter
Journal:  Nature       Date:  1996-04-11       Impact factor: 49.962

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  26 in total

1.  Prolyl isomerase Pin1 regulates neuronal differentiation via β-catenin.

Authors:  Kazuhiro Nakamura; Isao Kosugi; Daniel Y Lee; Angela Hafner; David A Sinclair; Akihide Ryo; Kun Ping Lu
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 2.  Prolyl isomerase Pin1 in cancer.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Cell Res       Date:  2014-08-15       Impact factor: 25.617

Review 3.  Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.

Authors:  Jane A Driver; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Biochim Biophys Acta       Date:  2015-01-10

4.  Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3β (GSK3β) activity: novel mechanism for Pin1 to protect against Alzheimer disease.

Authors:  Suk Ling Ma; Lucia Pastorino; Xiao Zhen Zhou; Kun Ping Lu
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

Review 5.  Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins.

Authors:  Yih-Cherng Liou; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Trends Biochem Sci       Date:  2011-08-17       Impact factor: 13.807

6.  Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease.

Authors:  Chun-Hau Chen; Wenzong Li; Rukhsana Sultana; Mi-Hyeon You; Asami Kondo; Koorosh Shahpasand; Byeong Mo Kim; Man-Li Luo; Morris Nechama; Yu-Min Lin; Yandan Yao; Tae Ho Lee; Xiao Zhen Zhou; Aaron M Swomley; D Allan Butterfield; Yan Zhang; Kun Ping Lu
Journal:  Neurobiol Dis       Date:  2015-01-06       Impact factor: 5.996

7.  Cis phosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offering novel diagnostic and therapeutic strategies.

Authors:  Kazuhiro Nakamura; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

Review 8.  The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.

Authors:  Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Rev Cancer       Date:  2016-06-03       Impact factor: 60.716

9.  Identification and characterization of transcriptional control region of the human beta 1,4-mannosyltransferase gene.

Authors:  Tetsuo Takahashi; Takashi Nedachi; Takuya Etoh; Hiroyuki Tachikawa; Xiao-Dong Gao
Journal:  Cytotechnology       Date:  2015-11-25       Impact factor: 2.058

Review 10.  Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease.

Authors:  Jane A Driver; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Discov Med       Date:  2014-02       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.